

## Acazicolcept

Cat. No.:	HY-P99420
CAS No.:	2797026-97-0
Target:	CD28
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities <sup>[1]</sup> .								
<b>In Vivo</b>	<p>Acazicolcept (267-400 µg/mouse; i.p.; twice a week; for 6 weeks) decreases dermal and pulmonary fibrosis and alleviates pulmonary hypertension<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>Six-week-old female BALB/c mice induced by hypochlorous acid (HOCL)<sup>[1]</sup></td></tr><tr><td>Dosage:</td><td>267 µg/mouse and 400 µg/mouse</td></tr><tr><td>Administration:</td><td>i.p.; twice a week; for 6 weeks</td></tr><tr><td>Result:</td><td>Induced a significant decrease in dermal thickness, collagen content, myofibroblast number, and inflammatory infiltrates characterized by B cells, T cells, neutrophils, and macrophages.</td></tr></table>	Animal Model:	Six-week-old female BALB/c mice induced by hypochlorous acid (HOCL) <sup>[1]</sup>	Dosage:	267 µg/mouse and 400 µg/mouse	Administration:	i.p.; twice a week; for 6 weeks	Result:	Induced a significant decrease in dermal thickness, collagen content, myofibroblast number, and inflammatory infiltrates characterized by B cells, T cells, neutrophils, and macrophages.
Animal Model:	Six-week-old female BALB/c mice induced by hypochlorous acid (HOCL) <sup>[1]</sup>								
Dosage:	267 µg/mouse and 400 µg/mouse								
Administration:	i.p.; twice a week; for 6 weeks								
Result:	Induced a significant decrease in dermal thickness, collagen content, myofibroblast number, and inflammatory infiltrates characterized by B cells, T cells, neutrophils, and macrophages.								

### REFERENCES

[1]. Cindy Orvain, et al. Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. *Arthritis Res Ther.* 2022 Jan 5;24(1):13.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA